Group 1 - The core viewpoint of the article highlights that Mao Geping (01318) has seen a stock price increase of nearly 3%, currently trading at 92.6 HKD with a transaction volume of 59.55 million HKD [1] - On February 5, the company announced that it received approval from the Hong Kong Stock Exchange to list and trade 228 million H-shares, which are the maximum number of unlisted shares convertible and to be listed [1] - Goldman Sachs' research indicates that despite challenges in the overall cosmetics industry, Mao Geping is expected to outperform the market, with projected compound annual growth rates (CAGR) for sales and net profit reaching 23% and 22% respectively from 2025 to 2027 [1] Group 2 - Shenwan Hongyuan forecasts that the company's GMV on Douyin is expected to grow by around 50% in 2025, with both skincare and makeup segments contributing to this growth [1] - The profit growth rate is anticipated to be 35% in 2025, indicating strong performance in the company's financial outlook [1]

省药监局相关处室负责人介绍，为切实提高药品监管能力，陕西药品监管"一体化"运行机制全面建 立运行，药品监管党政同责有效落实，省、市、县食品药品安全委员会机制健全，监管机构职能清晰、 运行顺畅。 2月5日，记者从省药监局获悉："十四五"以来，陕西药品监管系统持续深化监管改革，药品安全风 险防控得到有效落实，截至2025年底，陕西药品、疫苗、医疗器械、化妆品监管实现全覆盖。 在推进药品智慧监管建设方面，陕西已建成药品监管综合业务系统、陕西省疫苗（药品）追溯监管 系统、陕西省药品监管大数据中心，实现省、市、县三级药械化监管业务"一网通办"，疫苗、特殊药 品、血液制品、集采中选产品等重点药品实现全链条信息可追溯。全省药品监管各类信息集成共享，风 险识别、风险预警、风险处置实现闭环管理。（记者：周明） 为支持"两品一械"（药品、化妆品、医疗器械）产业高质量发展，"十四五"以来，陕西药监系统持 续深化审评审批制度改革，药械化创新取得显著成效。I类创新药甲磺酸普雷福韦片获批上市，实现陕 西I类创新药零的突破。5个三类医疗器械创新产品获批上市。2种化妆品新原料通过国家药监局备案。 196个品种药品通过或视同通过仿制药一致性评 ...

Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining attention in the global health industry for its potential in anti-aging, DNA repair, and metabolic regulation, with significant advancements in regulatory approval and market potential expected by 2025 [1][2]. Industry Development - The NMN industry has evolved from laboratory research to commercial application, with major markets like the US, Japan, Canada, and Australia recognizing its legal status through various regulatory pathways [1][2]. - China is currently the largest producer of NMN raw materials, with leading companies building competitive barriers through technological innovation and industry chain layout [2]. NMN Definition and Function - NMN is a direct precursor of NAD+ (Nicotinamide Adenine Dinucleotide), crucial for delaying aging and enhancing physiological functions [3][4]. - Supplementing NMN can quickly elevate NAD levels in the body, playing a vital role in anti-aging, cardiovascular health, and metabolic improvement [4]. NAD+ Synthesis Pathways - NMN supplementation shows significant advantages in NAD+ synthesis pathways compared to other precursors, with the highest conversion efficiency and no known adverse reactions [6][7]. Natural Sources of NMN - Natural food sources of NMN are limited, with NMN supplements providing approximately 300 times the intake efficiency compared to dietary sources [8]. NMN Synthesis Technology - The synthesis of NMN has transitioned from chemical methods to fully enzymatic methods, focusing on high purity, safety, and environmental sustainability [10][11]. - Leading companies are innovating in full enzymatic synthesis technology, establishing competitive advantages through patent applications [12]. Industry Development Drivers: Policy - The regulatory environment for NMN is evolving, with significant progress in China towards legalization as a health food, following the approval of NMN as a cosmetic ingredient [17][18]. Industry Development Drivers: Demand - The aging population and increasing anti-aging awareness among younger generations are driving demand for NMN products, creating a substantial market opportunity [19]. Industry Development Drivers: Technology - Innovations in synthesis, quality testing, and delivery methods are driving the NMN industry towards scale, standardization, and efficiency [21][22]. Application Areas of NMN - NMN is primarily used in health supplements and cosmetics, with potential expansion into pet nutrition, medical health, and agricultural technology [24][28]. Market Size and Growth - The NMN market in China is expected to exceed 3 billion yuan by 2025, driven by policy relaxation and new applications in various sectors [28]. Sales Channels - NMN products are primarily sold through cross-border e-commerce and private channels, with cross-border platforms accounting for 60%-70% of market share [35]. Certification System - The "blue hat" certification for health foods represents the highest standard in the NMN industry in China, indicating product safety and compliance [37]. Challenges Facing the NMN Industry - Despite positive regulatory signals, the industry faces challenges such as exaggerated claims, lack of consumer awareness, and the need for technological advancements [61][63].

2月5日，A股和港股行情有所分化。港股主要指数午后拉升，收盘逆势飘红。港股消费板块表现较为亮 眼，多只相关ETF涨幅居市场前列。 值得注意的是，在港股市场近日的震荡调整中，恒生科技指数大幅下挫。与大盘走势不尽如人意形成对 比的是，港股中的消费和红利板块展现出较强韧性，多只相关基金净值表现随之水涨船高。展望后市， 多家公募机构认为，港股仍处于全球估值洼地，短期扰动或不改中长期配置性价比，看好结构性投资机 会。 ● 本报记者 张韵 港股市场获关注 2月5日，港股主要指数在早盘下挫后震荡反弹，最终收红。恒生指数收盘报26885.24点，微涨0.14%； 恒生科技指数收盘报5406.13点，上涨0.74%。 回顾近期行情，港股市场整体处于震荡调整之中。尤其是2月2日，港股主要指数跳空低开，并大幅下 跌，引发较多关注。恒生科技指数当日跌幅达3.36%，随后连续下跌，更是在2月5日早盘触及阶段新 低，点位一度回撤至2025年7月水平。 业内人士分析，此轮调整的核心原因，源于市场对美联储政策转向的担忧。美联储主席新提名人选主张 的"降息+缩表"政策组合引发全球流动性预期扰动。港股作为离岸市场，容易成为资金波动的敏感地 带。 ...

2月5日，A股和港股行情有所分化。港股主要指数午后拉升，收盘逆势飘红。港股消费板块表现较为亮 眼，多只相关ETF涨幅居市场前列。 值得注意的是，在港股市场近日的震荡调整中，恒生科技指数大幅下挫。与大盘走势不尽如人意形成对 比的是，港股中的消费和红利板块展现出较强韧性，多只相关基金净值表现随之水涨船高。展望后市， 多家公募机构认为，港股仍处于全球估值洼地，短期扰动或不改中长期配置性价比，看好结构性投资机 会。 ● 本报记者张韵 港股市场获关注 2月5日，港股主要指数在早盘下挫后震荡反弹，最终收红。恒生指数收盘报26885.24点，微涨0.14%； 恒生科技指数收盘报5406.13点，上涨0.74%。 回顾近期行情，港股市场整体处于震荡调整之中。尤其是2月2日，港股主要指数跳空低开，并大幅下 跌，引发较多关注。恒生科技指数当日跌幅达3.36%，随后连续下跌，更是在2月5日早盘触及阶段新 低，点位一度回撤至2025年7月水平。 业内人士分析，此轮调整的核心原因，源于市场对美联储政策转向的担忧。美联储主席新提名人选主张 的"降息+缩表"政策组合引发全球流动性预期扰动。港股作为离岸市场，容易成为资金波动的敏感地 带。叠 ...

Market Overview - Financial markets experienced a significant downturn on February 5, with major U.S. stock indices opening lower, while Chinese concept stocks showed resilience [1][10] - The Nasdaq and S&P 500 indices both fell over 1% [1] Stock Performance - Dow Jones Industrial Average: 49,093.81, down 0.82% [2] - Nasdaq Index: 22,567.64, down 1.47% [2] - S&P 500: 6,807.73, down 1.09% [2] Precious Metals - International spot gold dropped nearly 3%, trading at $4,831.254 per ounce [2][3] - Spot silver fell over 15%, priced at $74.867 per ounce [2][3] - Year-to-date performance for gold shows an increase of 11.89%, while silver has risen by 4.60% [3][14] Company News - Estee Lauder's stock plummeted over 20% due to increased marketing costs and lower-than-expected earnings guidance for the year [3][14] - Qualcomm's stock fell over 9% after reporting Q1 revenue of $12.25 billion, a 5% year-on-year increase, but a 1% decline in adjusted net profit [5][18] - Alphabet (Google) shares dropped over 3% following the release of its Q4 report, which showed revenue of $113.8 billion, an 18% year-on-year increase. The company plans to nearly double its capital expenditure for 2026 [7][16] - Microsoft shares decreased by nearly 3% as the company focuses on enhancing AI functionality reliability, pausing aggressive new feature development [7][16] - Amazon's stock fell over 3% after the German Federal Cartel Office prohibited the company from interfering with seller pricing on its platform, ordering a return of approximately €59 million due to anti-competitive behavior [8][17] Chinese Concept Stocks - Nasdaq China Golden Dragon Index saw a rise of over 1%, with a current increase of 0.67% [10][17] - NIO's stock rose nearly 5% as the company anticipates its first quarterly profit by Q4 2025, driven by increased sales and a high-margin product mix [11][20] - Li Auto's stock increased over 3% with the announcement of the new Li L9 model, which is positioned as an intelligent vehicle [11][20] - XPeng Motors' stock rose over 2% with the upcoming launch of its flagship large six-seat SUV, the XPeng GX [11][20]

Core Viewpoint - Estée Lauder (EL.US) experienced a nearly 20% drop in stock price following the release of its Q2 FY2026 earnings, despite a 44% increase over the past year, currently trading at $96.49 [1] Financial Performance - The company reported Q2 sales of $4.23 billion, meeting analyst expectations [1] - Adjusted earnings per share (EPS) were $0.89, surpassing the forecast of $0.83 [1] Future Guidance - The company increased marketing expenditures for brand revitalization while facing cost pressures from tariffs, which are compressing profit margins and affecting annual profit expectations [1] - Full-year net sales growth guidance is set at 3% to 5%, with a midpoint of 4%, which is below the analyst expectation of 4.3% [1] - Adjusted EPS guidance is projected between $2.05 and $2.25, with a midpoint of $2.15, also falling short of the anticipated $2.16 [1]

智通财经APP获悉，周四，雅诗兰黛(EL.US)暴跌近20%，近一年已累涨44%，现报96.49美元。消息面 上，雅诗兰黛公布2026财年第二季度业绩，销售额为42.3亿美元，符合分析师的预期;调整后每股收益 为0.89美元，超过分析师预期的0.83美元。 不过，公司为品牌重塑增加营销支出，同时持续应对关税带来的成本压力，进一步压缩盈利空间并影响 全年盈利预期。全年净销售额增长指引为3%至5%，中间值4%低于分析师预期的4.3%;调整后每股收益 指引为2.05至2.25美元，中间值2.15美元亦低于预期的2.16美元。 ...

格隆汇2月5日｜雅诗兰黛公布去年第四季度业绩，销售额为42.3亿美元，符合分析师的预期；调整后每 股收益为0.89美元，超过分析师预期的0.83美元。展望今年，公司预计净销售额将增长3%至5%，中间 值低于分析师预期的增长4.3%；调整后每股收益将介于2.05至2.25美元之间，中间值亦低于预期的2.16 美元。雅诗兰黛正在通过增加营销支出进行品牌重塑，同时应对关税相关压力。 ...

坏消息是 ： 华熙生物旗下【润熙泉】，因公司内部业务调整， 以后就不做这个牌子了。 这个消息一出，直接炸了！ 目前某猫旗舰店已经关闭了，某音店 内商品全撤了， 某书也没更新了。 思的延伸阅读。 洞见 （DJ00123987） ——不一样的观点，不一样的故事，2000万人订阅的微信大号。点击标题下蓝字"洞见"关注，我们将为您提供有价值、有意 年末惊喜来袭！倾听者返场福利 预约直播，抢新年好礼 一个短暂的好消息和一个永久的坏消息。 很多人的心也跟着碎掉了，它家很多宝藏产品之后再也买不到了，呜呜呜。 华熙生物大家都熟， 连国际大品牌 （雅*兰黛、资*堂、H*R、海*之谜、*蔻等） 都抢着用的供应商！ 润熙泉，则是华熙生物的贵妇线，都上新闻的。 整个华熙生物好的成分、贵的成分、先进的技术， 几乎全数用在润熙泉里。 如今宣布全线停产，多少姐妹天塌了啊～因为 润熙泉的东西是真的好用。 好消息！ 今天我赶紧给大家薅到了一波 闭店羊毛 ！ 有需要的朋友直接买。错过这头，可能再也没有这么好用的华熙平价线了…… 润熙泉小银盾「四抗次抛」精华 规格： 1ml*30支/盒 有效期： 至202 6年10月-12月 清仓价 ： 59.9 ...